Antibody cocktail reduces COVID-19 hospitalization, death risk
Data this week by Eli Lilly showed treatment with a combination of the company’s COVID-19 neutralizing antibodies bamlanivimab and etesevimab reduced the risk of COVID-19 hospitalizations and deaths by 70% among a group of more than 1,000 high-risk patients enrolled in a Phase 3 clinical trial. Another trial using lower doses of the drugs also showed positive results, which could allow the company to extend its supplies to more people. In a separate , the Regeneron Pharmaceuticalssaid results from the Phase 3 trial of its COVID-19 antibody cocktail indicated it could work as a passive vaccine. The company reported half as many infections and no symptomatic infections in its treatment group (186 people) as compared to the placebo group (223 people). (Ely Lilly , 1/26/21)
